On 23 August 2024, Sandoz’s denosumab biosimilars, Jubbonti® and Wyost®, biosimilars to Amgen’s Prolia® and Xgeva® respectively, were approved in Australia. These are the first denosumab biosimilars approved in Australia.
This follows a number of denosumab biosimilar approvals overseas during the past two years, including in the US (Sandoz’s Jubbonti® and Wyost®, March 2024), Canada (Sandoz’s Jubbonti®, February 2024 and Wyost®, March 2024), Europe (Sandoz’s Jubbonti® and Wyost®, May 2024), China (Boan Biotech’s Byoubei® (November 2022) and Boluojia® (May 2024) and Mabwell’s and MaiweijianTM (April 2024)).